# US 2015/0105348 A1 · Compositions and methods for reducing lactate levels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105348 A1
- Document ID: US20150105348A1
- Status: Published application
- Kind: A1
- Application number: 14/491,714
- Filed: 2014-09-19
- Published: 2015-04-16
- Earliest claimed: 2013-09-24
- Applicants: The Regents of the University of California
- Inventors: Abhinav P. Acharya; Niren Murthy; Elliot C. Woods
- Web page: https://patentgrep.com/patent/US20150105348A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/69: Boron compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides methods of reducing levels of lactate in a fluid or tissue in an individual. The present disclosure provides pharmaceutical compositions suitable for use in the methods.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
a) a compound of formula I:
wherein Z1 is CH, CR1 or N;
Z2 is CH, CR2 or N;
Z3 is CH, CR3 or N;
R1, R2, R3, R4 and R5 are each independently selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl; and
b) a pharmaceutically acceptable excipient.

### Claim at position 2

-3. (canceled)

### Claim 4

A method of reducing the level of lactate in a fluid or tissue of an individual, the method comprising administering to the individual an effective amount of:
a) a compound of formula I:
wherein Z1 is CH, CR1 or N;
Z2 is CH, CR2 or N;
Z3 is CH, CR3 or N;
R1, R2, R3, R4 and R5 are each independently selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl;
b) a compound of formula II:
wherein R1, R2, R3, R4 and R5 are each independently selected from hydrogen, acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl;
c) a compound of formula III:
or
d) a pharmaceutical composition comprising a compound of (a), (b), or (c),
wherein said administering reduces the level of lactate in a fluid or tissue in the individual.

### Claim 5 (depends on 4)

The method of claim 4, wherein the fluid is blood or a blood fraction.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the individual is a mammal.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the individual is a human.

### Claim 8 (depends on 4)

The method according to claim 4, wherein an effective amount of the compound is in a range of from 10 μM to 500 mM.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 4)

The method according to claim 4, wherein said administering reduces the level of lactate in a fluid or tissue in the individual to less than 5 mM.

### Claim 12 (depends on 4)

The method according to claim 4, wherein said administering increases the blood pH of the individual by at least 0.02 pH units.

### Claim at position 11

-14. (canceled)

### Claim 15 (depends on 4)

The method according to claim 4, wherein the compound is administered in combination with an anti-cancer agent.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the anti-cancer agent is a cancer chemotherapeutic agent.

### Claim 17

(canceled)

### Claim 18

A method of treating a disease or disorder associated with elevated lactate in an individual, the method comprising:
administering to the individual an effective amount of:
a) a compound of formula I:
wherein Z1 is CH, CR1 or N;
Z2 is CH, CR2 or N;
Z3 is CH, CR3 or N;
R1, R2, R3, R4 and R5 are each independently selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl;
b) a compound of formula II:
wherein R1, R2, R3, R4 and R5 are each independently selected from hydrogen, acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl;
c) a compound of formula III:
or
d) a pharmaceutical composition comprising a compound of (a), (b), or (c),
wherein the compound selectively binds to lactate and reduces the level of lactate in a tissue or fluid in the individual, thereby treating the disease or disorder associated with elevated lactate in the individual.

### Claim 19 (depends on 18)

The method of claim 18, wherein the fluid is blood or a blood fraction.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the condition is lactic acidosis.

### Claim 21 (depends on 18)

The method according to claim 18, wherein the condition is cancer, non-Hodgkin's lymphoma, Burkitt lymphoma, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), diabetes mellitus and deafness (DAD), maternally inherited diabetes and deafness (MIDD), glucose-6-phosphatase deficiency, glycogen storage disease type I (GSD I), von Gierke's disease, fructose 1,6-diphosphatase deficiency, pyruvate dehydrogenase deficiency (PDCD), pyruvate carboxylase deficiency, diabetic ketoacidosis, regional hypoperfusion, hepatic disease, shock, sepsis, ethanol toxicity, hemorrhage, hypoxia, hypoperfusion, isoniazid toxicity, phenformin ingestion, metformin ingestion, nucleoside reverse transcriptase inhibitor ingestion, or cyanide ingestion.

### Claim 22 (depends on 18)

The method according to claim 18, wherein the individual is a mammal.

### Claim 23 (depends on 18)

The method according to claim 18, wherein the individual is a human.

### Claim 24 (depends on 18)

The method according to claim 18, wherein an effective amount of the compound is in a range of from 10 μM to 500 mM.

### Claim at position 22

-28. (canceled)

### Claim 29 (depends on 18)

The method according to claim 18, wherein said administering increases the blood pH of the individual by at least 0.02 pH units.

### Claim at position 24

-31. (canceled)

### Claim 32 (depends on 18)

The method according to claim 18, wherein the compound is administered in combination with an anti-cancer agent.

### Claim 33

(canceled)

### Claim 34

A method of treating lactic acidosis in an individual, the method comprising:
administering to the individual an effective amount of:
a) a compound of formula I:
wherein Z1 is CH, CR1 or N;
Z2 is CH, CR2 or N;
Z3 is CH, CR3 or N;
R1, R2, R3, R4 and R5 are each independently selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl;
b) a compound of formula II:
wherein R1, R2, R3, R4 and R5 are each independently selected from hydrogen, acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl, —SO2-heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl, and acyl;
c) a compound of formula III:
or
d) a pharmaceutical composition comprising a compound of (a), (b), or (c),
wherein the boronic acid compound selectively binds to lactate and treats the lactic acidosis.

### Claim at position 28

-36. (canceled)
